Illumina Inc - Asset Resilience Ratio
Illumina Inc (ILMN) has an Asset Resilience Ratio of 24.58% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Illumina Inc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2025)
This chart shows how Illumina Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Illumina Inc.
Liquid Assets Composition Over Time
This chart breaks down Illumina Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore ILMN long-term investments to assets to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $1.42 Billion | 21.34% |
| Short-term Investments | $215.00 Million | 3.24% |
| Total Liquid Assets | $1.63 Billion | 24.58% |
Asset Resilience Insights
- Good Liquidity Position: Illumina Inc maintains a healthy 24.58% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Illumina Inc Industry Peers by Asset Resilience Ratio
Compare Illumina Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Scope Fluidics SA
WAR:SCP |
Diagnostics & Research | 16.51% |
|
Eurofins-Cerep SA
PA:ALECR |
Diagnostics & Research | 13.42% |
|
Check-Cap Ltd
F:7CC |
Diagnostics & Research | 2.90% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
Annual Asset Resilience Ratio for Illumina Inc (1999–2025)
The table below shows the annual Asset Resilience Ratio data for Illumina Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 24.58% | $1.63 Billion | $6.64 Billion | +5.22pp |
| 2024-12-31 | 19.36% | $1.22 Billion | $6.30 Billion | +8.93pp |
| 2023-12-31 | 10.42% | $1.05 Billion | $10.11 Billion | -6.20pp |
| 2022-12-31 | 16.63% | $2.04 Billion | $12.25 Billion | +7.83pp |
| 2021-12-31 | 8.80% | $1.34 Billion | $15.22 Billion | -36.98pp |
| 2020-12-31 | 45.77% | $3.47 Billion | $7.58 Billion | +27.02pp |
| 2019-12-31 | 18.75% | $1.37 Billion | $7.32 Billion | -15.27pp |
| 2018-12-31 | 34.03% | $2.37 Billion | $6.96 Billion | +16.53pp |
| 2017-12-31 | 17.50% | $920.00 Million | $5.26 Billion | -1.75pp |
| 2016-12-31 | 19.25% | $824.21 Million | $4.28 Billion | +2.51pp |
| 2015-12-31 | 16.74% | $617.45 Million | $3.69 Billion | -4.30pp |
| 2014-12-31 | 21.04% | $702.22 Million | $3.34 Billion | +6.00pp |
| 2013-12-31 | 15.04% | $453.97 Million | $3.02 Billion | -20.67pp |
| 2012-12-31 | 35.71% | $916.22 Million | $2.57 Billion | -4.67pp |
| 2011-12-31 | 40.38% | $886.59 Million | $2.20 Billion | +5.29pp |
| 2010-12-31 | 35.09% | $645.34 Million | $1.84 Billion | -3.30pp |
| 2009-12-31 | 38.39% | $548.89 Million | $1.43 Billion | +15.65pp |
| 2008-12-31 | 22.73% | $313.05 Million | $1.38 Billion | +1.36pp |
| 2007-12-31 | 21.38% | $211.14 Million | $987.73 Million | -9.37pp |
| 2006-12-31 | 30.75% | $92.42 Million | $300.58 Million | -61.11pp |
| 2005-12-31 | 91.86% | $92.42 Million | $100.61 Million | +79.00pp |
| 2004-12-31 | 12.86% | $12.21 Million | $94.91 Million | -7.61pp |
| 2003-12-31 | 20.47% | $20.32 Million | $99.23 Million | -21.96pp |
| 2002-12-31 | 42.43% | $51.73 Million | $121.91 Million | -28.06pp |
| 2001-12-31 | 70.49% | $86.33 Million | $122.47 Million | +69.74pp |
| 2000-12-31 | 0.75% | $1.00 Million | $132.79 Million | -34.43pp |
| 1999-12-31 | 35.18% | $11.92 Million | $33.89 Million | -- |
About Illumina Inc
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and … Read more